AR077484A1 - Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion - Google Patents
Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracionInfo
- Publication number
- AR077484A1 AR077484A1 ARP100102598A ARP100102598A AR077484A1 AR 077484 A1 AR077484 A1 AR 077484A1 AR P100102598 A ARP100102598 A AR P100102598A AR P100102598 A ARP100102598 A AR P100102598A AR 077484 A1 AR077484 A1 AR 077484A1
- Authority
- AR
- Argentina
- Prior art keywords
- glatiramer acetate
- mannitol
- administration
- solution
- aqueous pharmaceutical
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title abstract 5
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title abstract 5
- 229960003776 glatiramer acetate Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 abstract 6
- 239000003186 pharmaceutical solution Substances 0.000 abstract 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 4
- 229930195725 Mannitol Natural products 0.000 abstract 4
- 235000010355 mannitol Nutrition 0.000 abstract 4
- 239000000594 mannitol Substances 0.000 abstract 4
- 239000000243 solution Substances 0.000 abstract 3
- 206010051290 Central nervous system lesion Diseases 0.000 abstract 1
- 230000005713 exacerbation Effects 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27100909P | 2009-07-15 | 2009-07-15 | |
| US27134009P | 2009-07-20 | 2009-07-20 | |
| US33701110P | 2010-01-29 | 2010-01-29 | |
| US12/761,367 US20110060279A1 (en) | 2009-07-15 | 2010-04-15 | Reduced Volume Formulation of Glatiramer Acetate and Methods of Administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077484A1 true AR077484A1 (es) | 2011-08-31 |
Family
ID=42283140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102598A AR077484A1 (es) | 2009-07-15 | 2010-07-15 | Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20110060279A1 (https=) |
| EP (2) | EP2275086B1 (https=) |
| JP (1) | JP2012533540A (https=) |
| AR (1) | AR077484A1 (https=) |
| AT (1) | ATE549013T1 (https=) |
| AU (1) | AU2010273234A1 (https=) |
| BR (1) | BR112012000878A2 (https=) |
| CA (1) | CA2697570C (https=) |
| DK (1) | DK2275086T3 (https=) |
| EA (1) | EA201270167A1 (https=) |
| ES (1) | ES2383347T3 (https=) |
| HR (1) | HRP20120349T1 (https=) |
| IL (1) | IL217240A0 (https=) |
| MX (1) | MX2012000687A (https=) |
| PL (1) | PL2275086T3 (https=) |
| PT (1) | PT2275086E (https=) |
| RS (1) | RS52367B (https=) |
| WO (1) | WO2011008274A2 (https=) |
| ZA (1) | ZA201200586B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US12097357B2 (en) | 2008-09-15 | 2024-09-24 | West Pharma. Services IL, Ltd. | Stabilized pen injector |
| CA2697570C (en) * | 2009-07-15 | 2011-11-01 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| NZ598661A (en) | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| CN104684603B (zh) * | 2012-08-20 | 2017-11-24 | 卡贝欧洲有限公司 | 自动注射装置 |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| WO2014128079A1 (en) * | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
| PE20151577A1 (es) * | 2013-03-08 | 2015-11-19 | Teva Pharma | Dispositivo inyector reutilizable para jeringa |
| US8591463B1 (en) | 2013-03-08 | 2013-11-26 | Teva Pharmaceutical Industries Ltd. | Re-useable injector device for syringe |
| BR112015021548A2 (pt) * | 2013-03-08 | 2017-07-18 | Teva Pharmaceutical Industries Ltd | dispositivo injetor reutilizável para seringa |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| EP3110375B1 (en) | 2014-02-26 | 2022-01-26 | Allergan, Inc. | Intraocular implant delivery apparatus |
| US9415176B1 (en) | 2015-01-22 | 2016-08-16 | West Pharmaceutical Services, Inc. | Autoinjector having an end-of-dose visual indicator |
| US9155775B1 (en) * | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| EP3534893A1 (en) * | 2016-11-02 | 2019-09-11 | To Pharmaceuticals LLC | Combination therapy of cbd and copaxone |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
| US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2017924B3 (es) * | 1985-10-11 | 1991-03-16 | Duphar Int Res B V | Inyector automatico. |
| NL8701091A (nl) * | 1987-05-08 | 1988-12-01 | Spruyt Hillen Bv | Injectiepen. |
| US5981485A (en) * | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| GB8926825D0 (en) * | 1989-11-28 | 1990-01-17 | Glaxo Group Ltd | Device |
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US6454746B1 (en) * | 1997-06-04 | 2002-09-24 | Eli Lilly And Company | Medication delivery apparatus |
| US20020077278A1 (en) * | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| SE518981C2 (sv) | 2000-12-14 | 2002-12-17 | Shl Medical Ab | Autoinjektor |
| AU2003275895B2 (en) * | 2002-11-25 | 2009-02-05 | Tecpharma Licensing Ag | Auto-injector comprising a resettable releasing safety device |
| JP2007507541A (ja) * | 2003-10-03 | 2007-03-29 | ベイヒル セラピューティクス インコーポレーティッド | 修飾型の規則正しいペプチドによる脱髄性自己免疫性疾患の治療方法 |
| US7655221B2 (en) * | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| EP1796710A4 (en) * | 2004-09-02 | 2010-05-26 | Teva Pharma | THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS |
| HRP20160455T1 (hr) * | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| AR052321A1 (es) * | 2004-10-29 | 2007-03-14 | Sandoz Ag | Procesos para la preparacion de un polipeptido |
| WO2007081975A2 (en) * | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US20070161960A1 (en) * | 2006-01-12 | 2007-07-12 | Fu-Yuan Li | Lancet device |
| US20080118553A1 (en) * | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| MX2008016335A (es) * | 2006-06-30 | 2009-01-21 | Abbott Biotech Ltd | Dispositivo automatico de inyeccion. |
| USD622374S1 (en) * | 2006-09-06 | 2010-08-24 | Abbott Biotechnology Ltd. | Automatic injection device |
| CA2702437C (en) * | 2007-11-28 | 2013-06-25 | Teva Pharmaceutical Industries Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| USD607558S1 (en) * | 2008-09-19 | 2010-01-05 | Becton Dickinson France S.A.S. | Medicine injector |
| CA2697570C (en) | 2009-07-15 | 2011-11-01 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
-
2010
- 2010-04-15 CA CA2697570A patent/CA2697570C/en not_active Expired - Fee Related
- 2010-04-15 ES ES10160099T patent/ES2383347T3/es active Active
- 2010-04-15 DK DK10160099.7T patent/DK2275086T3/da active
- 2010-04-15 US US12/761,367 patent/US20110060279A1/en not_active Abandoned
- 2010-04-15 PT PT10160099T patent/PT2275086E/pt unknown
- 2010-04-15 PL PL10160099T patent/PL2275086T3/pl unknown
- 2010-04-15 AT AT10160099T patent/ATE549013T1/de active
- 2010-04-15 RS RS20120188A patent/RS52367B/sr unknown
- 2010-04-15 EP EP10160099A patent/EP2275086B1/en active Active
- 2010-05-21 US US12/785,125 patent/US7855176B1/en not_active Expired - Fee Related
- 2010-07-14 MX MX2012000687A patent/MX2012000687A/es not_active Application Discontinuation
- 2010-07-14 JP JP2012520598A patent/JP2012533540A/ja active Pending
- 2010-07-14 AU AU2010273234A patent/AU2010273234A1/en not_active Abandoned
- 2010-07-14 WO PCT/US2010/001972 patent/WO2011008274A2/en not_active Ceased
- 2010-07-14 EP EP10800156A patent/EP2453907A2/en not_active Withdrawn
- 2010-07-14 BR BR112012000878A patent/BR112012000878A2/pt not_active IP Right Cessation
- 2010-07-14 EA EA201270167A patent/EA201270167A1/ru unknown
- 2010-07-15 AR ARP100102598A patent/AR077484A1/es unknown
- 2010-11-17 US US12/948,611 patent/US9018170B2/en not_active Expired - Fee Related
-
2011
- 2011-12-27 IL IL217240A patent/IL217240A0/en unknown
-
2012
- 2012-01-24 ZA ZA2012/00586A patent/ZA201200586B/en unknown
- 2012-04-18 HR HRP20120349AT patent/HRP20120349T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110066112A1 (en) | 2011-03-17 |
| BR112012000878A2 (pt) | 2019-09-24 |
| HRP20120349T1 (hr) | 2012-07-31 |
| WO2011008274A2 (en) | 2011-01-20 |
| US9018170B2 (en) | 2015-04-28 |
| WO2011008274A4 (en) | 2011-11-10 |
| AU2010273234A1 (en) | 2012-02-23 |
| DK2275086T3 (da) | 2012-07-09 |
| EP2453907A2 (en) | 2012-05-23 |
| CA2697570C (en) | 2011-11-01 |
| US20110060279A1 (en) | 2011-03-10 |
| IL217240A0 (en) | 2012-02-29 |
| HK1152249A1 (en) | 2012-02-24 |
| US7855176B1 (en) | 2010-12-21 |
| ZA201200586B (en) | 2013-10-30 |
| EP2275086B1 (en) | 2012-03-14 |
| ATE549013T1 (de) | 2012-03-15 |
| WO2011008274A3 (en) | 2011-09-22 |
| ES2383347T3 (es) | 2012-06-20 |
| PL2275086T3 (pl) | 2012-09-28 |
| RS52367B (sr) | 2012-12-31 |
| JP2012533540A (ja) | 2012-12-27 |
| EP2275086A1 (en) | 2011-01-19 |
| MX2012000687A (es) | 2012-09-07 |
| PT2275086E (pt) | 2012-05-18 |
| EA201270167A1 (ru) | 2012-08-30 |
| CA2697570A1 (en) | 2010-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077484A1 (es) | Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion | |
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| BRPI0707235B8 (pt) | formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual | |
| ES2904543T3 (es) | Tratamiento de la disfunción sexual | |
| BRPI0910341A2 (pt) | dispositivo para conservação, preparação espontanea e administração de um principio ativo | |
| MX386614B (es) | Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo. | |
| JP2015513309A5 (https=) | ||
| BR112014015482A2 (pt) | compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática | |
| CO6150188A2 (es) | Uso de teencteplasa para tratar un ictus isquemico agudo | |
| CL2009002183A1 (es) | Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica. | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| BR112013005673A2 (pt) | uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| MX2019007779A (es) | Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe). | |
| EP4700016A3 (en) | Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof | |
| WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| Bowe et al. | Therapeutic update: acne | |
| RU2011139015A (ru) | Вызываемая медикаментозными средствами липоатрофия для косметических целей | |
| BR112014004339A2 (pt) | suspensão oral | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
| MX2019002657A (es) | Combinaciones con un peptido con esqueleto ciclado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |